Clinical trials: Ovary Cancer
Metastatic Fallopian Tube Carcinoma, Metastatic Ovarian Carcinoma
Carboplatin, Gemcitabine Hydrochloride, and Berzosertib in Treating Patients With Recurrent and Metastatic Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
This phase I trial studies the side effects and best dose of gemcitabine hydrochloride and berzosertib when given together with carboplatin in treating patients with ovarian, primary peritoneal, or fallopian tube cancer that has…
- Conditions
- Metastatic Fallopian Tube Carcinoma, Metastatic Ovarian Carcinoma, Metastatic Primary Peritoneal Carcinoma, Ovarian Endometrioid Tumor
- Trial name
- NCT02627443
- Testing
- Berzosertib, Carboplatin, Gemcitabine Hydrochloride
- Where
- 14 sites in United States
- Volunteers
- 35 people
- Sponsor
- National Cancer Institute (NCI)
Melanoma, Prostate Cancer
A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors
This is a first-in-human, open-label, dose escalation study to evaluate the safety and tolerability of pegilodecakin in participants with advanced solid tumors, dosed daily subcutaneously as a monotherapy or in combination with…
- Conditions
- Melanoma, Prostate Cancer, Ovarian Cancer, Renal Cell Carcinoma
- Trial name
- IVY (NCT02009449)
- Testing
- Pegilodecakin, Paclitaxel or Docetaxel and Carboplatin or Cisplatin, FOLFOX (Oxaliplatin/Leucovorin/5-Fluorouracil)
- Where
- 10 sites in United States
- Volunteers
- 353 people
- Sponsor
- Eli Lilly and Company
Ovarian Cancer
A Study of the Addition of Avastin (Bevacizumab) to Carboplatin and Paclitaxel Therapy in Patients With Ovarian Cancer
This open-label, non-comparative, multi-center study will assess the safety profile and efficacy of Avastin (bevacizumab) when added to carboplatin and paclitaxel therapy in participants with epithelial ovarian cancer, fallopian…
- Trial name
- NCT01239732
- Testing
- Paclitaxel, Bevacizumab, Carboplatin
- Where
- 242 sites in Argentina, Austria and 35 more
- Volunteers
- 1,021 people
- Sponsor
- Hoffmann-La Roche
Ovarian Cancer
Effect of 2-h Infusion of ON 01910.Na in Ovarian Cancer Patients
ON 01910.Na has undergone preclinical and clinical phase I studies showing activity in patients with progressing ovarian cancer resistant to platinum-based chemotherapies.
- Trial name
- NCT00856791
- Testing
- ON 01910.Na
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Traws Pharma, Inc.
Fallopian Tube Cancer, Ovarian Cancer
S0904: Docetaxel With or Without Vandetanib in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
RATIONALE: Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Trial name
- NCT00872989
- Testing
- docetaxel, vandetanib
- Where
- 137 sites in United States
- Volunteers
- 129 people
- Sponsor
- SWOG Cancer Research Network
Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma
Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer
This randomized phase II/III trial studies how well cediranib maleate and olaparib work when given together or separately, and compares them to standard chemotherapy in treating patients with ovarian, fallopian tube, or primary…
- Conditions
- Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma
- Trial name
- NCT02502266
- Testing
- Cediranib, Cediranib Maleate, Computed Tomography
- Where
- 398 sites in United States, Canada and 3 more
- Volunteers
- 582 people
- Sponsor
- National Cancer Institute (NCI)
Epithelial Ovarian Cancer, Peritoneal Cancer
A Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression
This study is designed to evaluate the efficacy and safety of mirvetuximab soravtansine (MIRV) in participants with platinum-resistant high-grade serous epithelial ovarian cancer, primary peritoneal, or fallopian tube cancer…
- Conditions
- Epithelial Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
- Trial name
- SORAYA (NCT04296890)
- Testing
- Mirvetuximab Soravtansine
- Where
- 89 sites in United States, Australia and 9 more
- Volunteers
- 106 people
- Sponsor
- ImmunoGen, Inc.
Cancer
Antithymocyte Globulin, Clofarabine, and Rituximab in Treating Patients After an Unsuccessful Stem Cell Transplant
RATIONALE: Antithymocyte globulin, clofarabine, and rituximab may stop the patient's immune system from rejecting the donor's stem cells when they do not exactly match the patient's blood.
- Trial name
- NCT00617929
- Testing
- anti-thymocyte globulin, rituximab, clofarabine
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Ovarian Cancer, Fallopian Tube Cancer
Accelerating Gastrointestinal Recovery
This study is designed to determine whether an oral perioperative medication (alvimopan--a selective mu antagonist) improves bowel recovery over placebo after surgery for ovarian cancer.
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
- Trial name
- NCT01704651
- Testing
- Alvimopan
- Where
- United States
- Volunteers
- 146 people
- Sponsor
- Jamie N. Bakkum-Gamez
Polycystic Ovarian Syndrome
The Efficacy and Safety Study of Tung's Acupuncture for Polycystic Ovarian Syndrome
This study evaluates the efficacy and safety in improving ovarian function of polycystic ovarian syndrome in adults. Half of patients will receive Tung's acupuncture therapy, while the other half will receive Diane-35(CPA/EE) as…
- Trial name
- NCT02729545
- Testing
- Tung's acupuncture, Cyproterone acetate/ethinylestradiol (CPA/EE)
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Beijing Hospital of Integrated Traditional Chinese and Western Medicine
Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma
Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Peritoneal Cancer, or Fallopian Tube Cancer
This randomized phase III trial studies paclitaxel to see how well it works compared to polyglutamate paclitaxel or observation only in treating patients with stage III or stage IV ovarian epithelial, peritoneal cancer, or…
- Conditions
- Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma
- Trial name
- NCT00108745
- Testing
- Clinical Observation, Laboratory Biomarker Analysis, Paclitaxel
- Where
- 315 sites in United States
- Volunteers
- 1,157 people
- Sponsor
- GOG Foundation
BRCA1 Gene Mutation, BRCA2 Gene Mutation
Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and Genomic Instability
This phase II trial studies how well pembrolizumab works in treating participants with cancer that has spread to other places in the body, has come back or has spread to nearby tissues or lymph nodes.
- Conditions
- BRCA1 Gene Mutation, BRCA2 Gene Mutation, Locally Advanced Solid Neoplasm, Metastatic Malignant Solid Neoplasm
- Trial name
- NCT03428802
- Testing
- Laboratory Biomarker Analysis, Pembrolizumab
- Where
- 2 sites in United States
- Volunteers
- 21 people
- Sponsor
- Rutgers, The State University of New Jersey
Ovarian Cancer
Gemcitabine in Ovarian Cancer
The primary endpoint of this study is to assess the objective tumor response rate in patients with advanced epithelial ovarian cancer receiving combination of Gemcitabine at a dose 1250 mg/m2 (Day 1 and 8) with Cisplatin 75 mg/m2…
- Trial name
- NCT00191334
- Testing
- gemcitabine, cisplatin
- Where
- 5 sites in Russia
- Volunteers
- 50 people
- Sponsor
- Eli Lilly and Company
Ovarian Cancer, Basal Cell Carcinoma
A Study of Vismodegib (GDC-0449) in Patients Treated With Vismodegib in a Previous Genentech-sponsored Phase I or II Cancer Study
This was a multicenter, open-label extension study. Patients who received vismodegib (GDC-0449) in a Genentech-sponsored study and who had completed the parent study or who continued to receive vismodegib at the time the parent…
- Conditions
- Ovarian Cancer, Basal Cell Carcinoma, Metastatic Colorectal Cancer
- Trial name
- NCT00959647
- Testing
- Vismodegib, FOLFOX, FOLFIRI
- Where
- 10 sites in United States
- Volunteers
- 19 people
- Sponsor
- Genentech, Inc.
Polycystic Ovary Syndrome, PCOS
Combination Metformin and Oral Contraception for Polycystic Ovary Syndrome (PCOS)
The purpose of this research study is to determine if adding Metformin, a drug that reduces insulin resistance, to birth control pills will reduce the risk of developing type 2 diabetes, high blood pressure.
- Conditions
- Polycystic Ovary Syndrome, PCOS, Insulin Sensitivity
- Trial name
- NCT00682890
- Testing
- metformin
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Virginia Commonwealth University
Ovarian Cancer, Ovarian Neoplasms
Study of Maplirpacept (PF-07901801) in Combination With PLD in Patients With Platinum-Resistant Ovarian Cancer
Pegylated liposomal doxorubicin (PLD), a type of chemotherapy, is a standard treatment option for patients with platinum-resistant ovarian cancer.
- Conditions
- Ovarian Cancer, Ovarian Neoplasms, Ovarian Carcinoma, Fallopian Tube Cancer
- Trial name
- NCT05261490
- Testing
- maplirpacept (PF-07901801), Pegylated Liposomal Doxorubicin (PLD)
- Where
- 18 sites in United States
- Volunteers
- 10 people
- Sponsor
- Pfizer
Fallopian Tube Cancer, Female Reproductive Cancer
Ziv-aflibercept in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gynecologic Soft Tissue Sarcoma
This phase II trial is studying how well ziv-aflibercept works in treating patients with locally advanced, unresectable or metastatic gynecologic soft tissue sarcoma.
- Conditions
- Fallopian Tube Cancer, Female Reproductive Cancer, Ovarian Carcinosarcoma, Ovarian Sarcoma
- Trial name
- NCT00390234
- Testing
- ziv-aflibercept
- Where
- 16 sites in United States, Canada
- Volunteers
- 63 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Ovarian Cancer, Primary Peritoneal Cancer
Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA Mutations
Background: The poly (ADP-ribose) polymerase (PARP) family of enzymes is critical for maintaining genomic stability by regulating a variety of deoxyribonucleic acid (DNA) damage repair mechanisms.
- Conditions
- Advanced Ovarian Cancer, Primary Peritoneal Cancer, Advanced Breast Cancer, Advanced Solid Tumors
- Trial name
- NCT01989546
- Testing
- BMN 673
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- National Cancer Institute (NCI)
Cancer
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
This is a phase III, randomized, double-blind, placebo-controlled, multicenter study of the clinical response to fentanyl sublingual spray as a treatment for breakthrough cancer pain.
- Trial name
- NCT00538850
- Testing
- Fentanyl sublingual spray
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- INSYS Therapeutics Inc
Breast Cancer, Colorectal Cancer
Expectations and Priorities of Elderly Patients for a First Medical Treatment for Cancer
The main objective of study is to describe the priorities of elderly patients (70 years and over) undergoing a first medical treatment for cancer, at initiation of treatment and after 3 months of treatment.
- Conditions
- Breast Cancer, Colorectal Cancer, Kidney Cancer, Lung Cancer
- Trial name
- PRIORITY (NCT02821793)
- Testing
- Consultation, evaluation questionnaire, Geriatric consultation, evaluation questionnaire
- Where
- France
- Volunteers
- 346 people
- Sponsor
- Institut Bergonié